{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:33Z","timestamp":1793774793285,"version":"4.6.1"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pharmthera.2020.107705","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:33:39Z","timestamp":1602203619000},"page":"107705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":242,"special_numbering":"C","title":["PPAR\u03b3\/PGC1\u03b1 signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders"],"prefix":"10.1016","volume":"219","author":[{"given":"Sumit","family":"Jamwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Elsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107705_bb0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fnins.2019.00292","article-title":"The role of PGC1\u03b1\/UCP2 signaling in the beneficial effects of physical exercise on the brain","volume":"13","author":"Aguiar","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrn1767","article-title":"Mitochondrial uncoupling proteins in the CNS: in support of function and survival","volume":"6","author":"Andrews","year":"2005","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0015","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1523\/JNEUROSCI.3890-09.2009","article-title":"Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism","volume":"29","author":"Andrews","year":"2009","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1523\/JNEUROSCI.4269-04.2005","article-title":"Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson\u2019s disease","volume":"25","author":"Andrews","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/bies.10138","article-title":"Mitochondrial dysfunction and Down's syndrome","volume":"24","author":"Arbuzova","year":"2002","journal-title":"Bioessays"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fendo.2019.00524","article-title":"Irisin: a hope in understanding and managing obesity and metabolic syndrome","volume":"10","author":"Arhire","year":"2019","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/cdd.2012.81","article-title":"The pathways of mitophagy for quality control and clearance of mitochondria","volume":"20","author":"Ashrafi","year":"2013","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0040","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1242\/jcs.113662","article-title":"PGC1\u03b1 and mitochondrial metabolism\u2013emerging concepts and relevance in ageing and neurodegenerative disorders","volume":"125","author":"Austin","year":"2012","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.2011.245","article-title":"Mitochondrial recoupling: a novel therapeutic strategy for cancer?","volume":"105","author":"Baffy","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.458","article-title":"PGC1\u03b1 buffers ROS-mediated removal of mitochondria during myogenesis","volume":"5","author":"Baldelli","year":"2014","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/biology8020037","article-title":"Mitochondrial dysfunction and multiple sclerosis","volume":"8","author":"Barcelos","year":"2019","journal-title":"Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0065","doi-asserted-by":"crossref","first-page":"864140","DOI":"10.1155\/2008\/864140","article-title":"Regulation of Glial Cell Functions by PPAR-\u03b3 Natural and Synthetic Agonists","volume":"2008","author":"Bernardo","year":"2008","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2015.10.011","article-title":"Mitochondrial fusion\/fission dynamics in neurodegeneration and neuronal plasticity","volume":"90","author":"Bertholet","year":"2016","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0075","first-page":"1066","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders\u2014A step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochemica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0080","doi-asserted-by":"crossref","first-page":"113324","DOI":"10.1016\/j.expneurol.2020.113234","article-title":"Pioglitazone activates paraoxonase-2 in the brain: a novel neuroprotective mechanism","volume":"327","author":"Blackburn","year":"2020","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jnnp.2005.077495","article-title":"PPARs: a new target for neuroprotection","volume":"77","author":"Bordet","year":"2006","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0095","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.bbamcr.2016.04.013","article-title":"UCPs, at the interface between bioenergetics and metabolism","volume":"1863","author":"Bouillaud","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1042\/bse0470069","article-title":"Regulation of mitochondrial biogenesis","volume":"47","author":"Brown","year":"2010","journal-title":"Essays in Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0105","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/ijms19061738","article-title":"Functional regulation of PPARs through post-translational modifications","volume":"19","author":"Brunmeir","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0110","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.bbabio.2018.05.019","article-title":"Mitochondrial uncoupling, ROS generation and cardioprotection","volume":"1859","author":"Cadenas","year":"2018","journal-title":"Biochimica et Biophysica Acta (BBA)-Bioenergetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0115","doi-asserted-by":"crossref","first-page":"D1251","DOI":"10.1093\/nar\/gkv1003","article-title":"MitoCarta2. 0: an updated inventory of mammalian mitochondrial proteins","volume":"44","author":"Calvo","year":"2016","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0120","doi-asserted-by":"crossref","first-page":"a028985","DOI":"10.1101\/cshperspect.a028985","article-title":"Neurodegeneration in progressive multiple sclerosis","volume":"8","author":"Campbell","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0125","doi-asserted-by":"crossref","first-page":"616371","DOI":"10.1155\/2012\/616371","article-title":"PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways","volume":"2012","author":"Camps","year":"2012","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOL.0b013e328328d0a4","article-title":"PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure","volume":"20","author":"Cant\u00f3","year":"2009","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biochi.2019.01.001","article-title":"FNDC5: a novel player in metabolism and metabolic syndrome","volume":"158","author":"Cao","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson\u2019s disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1242\/dmm.008227","article-title":"Parkin\u2019 control: regulation of PGC1\u03b1 through PARIS in Parkinson\u2019s disease","volume":"4","author":"Castillo-Quan","year":"2011","journal-title":"Disease Models & Mechanisms"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0155","doi-asserted-by":"crossref","first-page":"2105607","DOI":"10.1155\/2019\/2105607","article-title":"Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view","volume":"2019","author":"Cenini","year":"2019","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0160","article-title":"A truncated PPAR gamma 2 localizes to mitochondria and regulates mitochondrial respiration in brown adipocytes","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0165","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","article-title":"Impaired PGC1\u03b1 function in muscle in Huntington\u2019s disease","volume":"18","author":"Chaturvedi","year":"2009","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0170","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1093\/hmg\/ddq229","article-title":"Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington\u2019s disease following chronic energy deprivation","volume":"19","author":"Chaturvedi","year":"2010","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/biology8020038","article-title":"Mitochondrial dysfunction in parkinson\u2019s disease\u2014cause or consequence?","volume":"8","author":"Chen","year":"2019","journal-title":"Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0180","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.3390\/ijms19113447","article-title":"PGC1\u03b1 as a pivotal factor in lipid and metabolic regulation","volume":"19","author":"Cheng","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0185","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fnins.2018.00163","article-title":"The association of tau with mitochondrial dysfunction in alzheimer's disease","volume":"12","author":"Cheng","year":"2018","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0195","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/hmg\/ddq322","article-title":"Modulation of energy deficiency in Huntington\u2019s disease via activation of the peroxisome proliferator-activated receptor gamma","volume":"19","author":"Chiang","year":"2010","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.yexcr.2015.09.005","article-title":"Rosiglitazone activation of PPAR\u03b3-dependent signaling is neuroprotective in mutant huntingtin expressing cells","volume":"338","author":"Chiang","year":"2015","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0205","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.nbd.2011.08.016","article-title":"PPAR gamma rescue of the mitochondrial dysfunction in Huntington\u2019s disease","volume":"45","author":"Chiang","year":"2012","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0210","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/hmg\/ddr618","article-title":"Sustained expression of PGC1\u03b1 in the rat nigrostriatal system selectively impairs dopaminergic function","volume":"21","author":"Ciron","year":"2012","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048925","article-title":"PGC1\u03b1 overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased BDNF","volume":"7","author":"Clark","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0225","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade","volume":"64","author":"Cline","year":"2018","journal-title":"Journal of Alzheimers Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.expneurol.2013.12.012","article-title":"PPAR\u03b3 activation rescues mitochondrial function from inhibition of complex I and loss of PINK1","volume":"253","author":"Corona","year":"2014","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0235","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11064-014-1377-0","article-title":"PPAR\u03b3 and PGC1\u03b1 as therapeutic targets in Parkinson\u2019s","volume":"40","author":"Corona","year":"2015","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","article-title":"PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease","volume":"100","author":"Corona","year":"2016","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0245","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/biomedicines7010014","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis","volume":"7","author":"Correale","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0255","series-title":"Neurotoxicity of Metals","first-page":"85","article-title":"Metals and paraoxonases","volume":"18","author":"Costa","year":"2017"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuro.2013.08.011","article-title":"Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection","volume":"43","author":"Costa","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0265","series-title":"Nutraceuticals - Efficacy, Safety and Toxicity","first-page":"3","article-title":"Nutraceuticals in CNS diseases: potential mechanisms of neuroprotection","author":"Costa","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC1\u03b1 by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0275","first-page":"52","article-title":"The complex interaction of mitochondrial genetics and mitochondrial pathways in psychiatric disease","volume":"4","author":"Cuperfain","year":"2018","journal-title":"Molecular Neuropsychiatry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0280","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cmet.2012.03.019","article-title":"Elevated PGC1\u03b1 activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS","volume":"15","author":"Da Cruz","year":"2012","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0285","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cmet.2012.03.019","article-title":"Elevated PGC1\u03b1 activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS","volume":"15","author":"Da Cruz","year":"2012","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0290","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2015.07.014","article-title":"Peroxisome proliferator activated receptor-\u03b3 agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: Effects on mitochondrial functions and differentiation","volume":"271","author":"De Nuccio","year":"2015","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0300","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fneur.2018.00698","article-title":"Endocrine crosstalk between skeletal muscle and the brain","volume":"9","author":"Delezie","year":"2018","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0305","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cells8080795","article-title":"Mitochondrial uncoupling: a key controller of biological processes in physiology and diseases","volume":"8","author":"Demine","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0310","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.2174\/0929867324666170616110111","article-title":"The role of mitochondrial dysfunction in the progression of Alzheimer\u2019s disease","volume":"25","author":"Desler","year":"2018","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0315","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41419-018-0395-2","article-title":"Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer","volume":"9","author":"Devarajan","year":"2018","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0320","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1074\/jbc.M707587200","article-title":"Nuclear respiratory factor 1 regulates all ten nuclear-encoded subunits of cytochrome c oxidase in neurons","volume":"283","author":"Dhar","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0325","series-title":"Mitochondrial mechanisms of degeneration and repair in Parkinson\u2019s disease","first-page":"231","article-title":"Transcription modulation of mitochondrial function and related pathways as a therapeutic opportunity in parkinson\u2019s disease","author":"Dickey","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0330","doi-asserted-by":"crossref","first-page":"10766","DOI":"10.1523\/JNEUROSCI.2744-08.2008","article-title":"Exercise-induced synaptogenesis in the hippocampus is dependent on UCP2-regulated mitochondrial adaptation","volume":"28","author":"Dietrich","year":"2008","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2015.04.036","article-title":"The emerging role of Nrf2 in mitochondrial function","volume":"88","author":"Dinkova-Kostova","year":"2015","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0340","doi-asserted-by":"crossref","first-page":"a015008","DOI":"10.1101\/cshperspect.a015008","article-title":"Mitochondrial biogenesis through activation of nuclear signaling proteins","volume":"5","author":"Dominy","year":"2013","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0345","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1194\/jlr.M400511-JLR200","article-title":"Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities","volume":"46","author":"Draganov","year":"2005","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0350","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1096\/fj.13-236331","article-title":"PGC-1\u03b1: overexpression exacerbates \u03b2-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease","volume":"28","author":"Dumont","year":"2014","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0355","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jmb.2019.06.031","article-title":"Quality Control in Neurons: Mitophagy and Other Selective Autophagy Mechanisms","volume":"432","author":"Evans","year":"2020","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0360","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12640-017-9766-1","article-title":"Huntington\u2019s disease and mitochondria","volume":"32","author":"Farshbaf","year":"2017","journal-title":"Neurotoxicity Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0370","doi-asserted-by":"crossref","first-page":"5716415","DOI":"10.1155\/2016\/5716415","article-title":"Natalizumab treatment modulates peroxisome proliferator-activated receptors expression in women with multiple sclerosis","volume":"2016","author":"Ferret-Sena","year":"2016","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0375","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/brain\/aws012","article-title":"NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury","volume":"135","author":"Fischer","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnhum.2017.00017","article-title":"Contribution of neuroepigenetics to Huntington\u2019s disease","volume":"11","author":"Francelle","year":"2017","journal-title":"Frontiers in Human Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0390","doi-asserted-by":"crossref","first-page":"9757201","DOI":"10.1155\/2019\/9757201","article-title":"Mitochondrial Dynamics: Biogenesis, Fission, Fusion, and Mitophagy in the Regulation of Stem Cell Behaviors","volume":"2019","author":"Fu","year":"2019","journal-title":"Stem Cells International"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0395","doi-asserted-by":"crossref","first-page":"37006","DOI":"10.1074\/jbc.M700447200","article-title":"Peroxisome proliferator-activated receptor \u03b3 up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis","volume":"282","author":"Fuenzalida","year":"2007","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0400","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2016.05.036","article-title":"Paraoxonases-1,-2 and-3: what are their functions?","volume":"259","author":"Furlong","year":"2016","journal-title":"Chemico-Biological Interactions"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0405","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/antiox6020025","article-title":"Abnormalities of mitochondrial dynamics in neurodegenerative diseases","volume":"6","author":"Gao","year":"2017","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0410","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cbi.2016.04.001","article-title":"Developmental expression of paraoxonase 2","volume":"259","author":"Garrick","year":"2016","journal-title":"Chemico-Biological Interactions"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0415","doi-asserted-by":"crossref","first-page":"dvx009","DOI":"10.1093\/eep\/dvx009","article-title":"An emerging role for epigenetic regulation of PGC1\u03b1 expression in environmentally stimulated brown adipose thermogenesis","volume":"3","author":"Gill","year":"2017","journal-title":"Environmental Epigenetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0420","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.taap.2011.02.014","article-title":"Paraoxonase 2 (PON2) in the mouse central nervous system: a neuroprotective role?","volume":"256","author":"Giordano","year":"2011","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0425","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.freeradbiomed.2013.01.019","article-title":"Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression","volume":"58","author":"Giordano","year":"2013","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cns.12655","article-title":"Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment","volume":"23","author":"Golpich","year":"2017","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0435","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fnins.2019.00938","article-title":"Impairment of mitochondrial redox status in peripheral lymphocytes of multiple sclerosis patients","volume":"13","author":"Gonzalo","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0440","doi-asserted-by":"crossref","first-page":"2010675","DOI":"10.1155\/2018\/2010675","article-title":"Signaling Mechanisms of Selective PPAR\u03b3 Modulators in Alzheimer\u2019s Disease","volume":"2018","author":"Govindarajulu","year":"2018","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0445","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jnc.14037","article-title":"Brain aging and neurodegeneration: from a mitochondrial point of view","volume":"143","author":"Grimm","year":"2017","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0450","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Nutrition Journal"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0455","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fgene.2019.00435","article-title":"Regulation of mitochondrial biogenesis as a way for active longevity: interaction between the Nrf2 and PGC1\u03b1 signaling pathways","volume":"10","author":"Gureev","year":"2019","journal-title":"Frontiers in Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0460","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fnins.2019.00201","article-title":"Cell Autonomous Neuroprotection by the Mitochondrial Uncoupling Protein 2 in a Mouse Model of Glaucoma","volume":"13","author":"Hass","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0465","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPAR\u03b3 agonist pioglitazone and ibuprofen reduces glial inflammation and A\u03b21\u201342 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0470","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.molmet.2016.04.002","article-title":"Role of mitochondrial uncoupling protein-2 (UCP2) in higher brain functions, neuronal plasticity and network oscillation","volume":"5","author":"Hermes","year":"2016","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0475","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-9158-1-3","article-title":"Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson\u2019s disease","volume":"1","author":"Ho","year":"2012","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0480","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cotox.2016.10.002","article-title":"The multifaceted role of Nrf2 in mitochondrial function","volume":"1","author":"Holmstr\u00f6m","year":"2016","journal-title":"Current Opinion in Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0485","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yexcr.2004.09.032","article-title":"Peroxisome proliferator-activated receptor \u03b3 is expressed in hippocampal neurons and its activation prevents \u03b2-amyloid neurodegeneration: role of Wnt signaling","volume":"304","author":"Inestrosa","year":"2005","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0490","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fncel.2019.00103","article-title":"Mitochondrial Dysfunction in Huntington\u2019s Disease; Interplay Between HSF1, p53 and PGC1\u03b1 Transcription Factors","volume":"13","author":"Intihar","year":"2019","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0495","series-title":"Source hormones, metabolism and the benefits of exercise","first-page":"93","article-title":"The role of FNDC5\/Irisin in the nervous system and as a mediator for beneficial effects of exercise on the brain. hormones, metabolism and the benefits of exercise","author":"Islam","year":"2017"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0500","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/hmg\/ddu157","article-title":"NRIP1\/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome","volume":"23","author":"Izzo","year":"2014","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0505","doi-asserted-by":"crossref","first-page":"8737649","DOI":"10.1155\/2017\/8737649","article-title":"Overexpression of chromosome 21 miRNAs may affect mitochondrial function in the hearts of down syndrome fetuses","volume":"2017","author":"Izzo","year":"2017","journal-title":"International Journal of Genomics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0510","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s10020-018-0004-y","article-title":"Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets","volume":"24","author":"Izzo","year":"2018","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0515","first-page":"1056","article-title":"Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in down syndrome cells","volume":"26","author":"Izzo","year":"2017","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0520","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.10.033","article-title":"Antidepressants for neuroprotection in Huntington's disease: A review","volume":"769","author":"Jamwal","year":"2015","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0525","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.physbeh.2015.12.015","article-title":"Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: possible role of oxidative stress, neuroinflammation, and neurotransmitters","volume":"155","author":"Jamwal","year":"2016","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0530","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antiox7010013","article-title":"Reactive oxygen species and mitochondrial dynamics: the yin and yang of mitochondrial dysfunction and cancer progression","volume":"7","author":"Je\u017eek","year":"2018","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0535","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0183-16.2016","article-title":"Adult conditional knockout of PGC1\u03b1 leads to loss of dopamine neurons","volume":"3","author":"Jiang","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0540","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-015-0037-x","article-title":"Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis","volume":"4","author":"Jiang","year":"2015","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0545","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jnc.12190","article-title":"Neuroprotective effects of PPAR-\u03b3 agonist rosiglitazone in N171-82Q mouse model of Huntington\u2019s disease","volume":"125","author":"Jin","year":"2013","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0550","article-title":"Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPAR\u03b3","volume":"7","author":"Jin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0555","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10863-010-9286-7","article-title":"The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease","volume":"42","author":"Jin","year":"2010","journal-title":"Journal of Bioenergetics and Biomembranes"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0560","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.112.192138","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"342","author":"Johri","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0565","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","article-title":"Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease","volume":"21","author":"Johri","year":"2011","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0570","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","article-title":"PGC1\u03b1, mitochondrial dysfunction, and Huntington\u2019s disease","volume":"62","author":"Johri","year":"2013","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0575","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.11.020","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production","volume":"253","author":"Jung","year":"2007","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0580","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12522-013-0162-0","article-title":"Dynamic regulation of mitochondrial genome maintenance in germ cells","volume":"13","author":"Kasashima","year":"2014","journal-title":"Reproductive Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0585","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2011-101356","article-title":"PPAR\u03b3 co-activator-1\u03b1 (PGC1\u03b1) reduces amyloid-\u03b2 generation through a PPAR\u03b3-dependent mechanism","volume":"25","author":"Katsouri","year":"2011","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0590","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1091\/mbc.e07-05-0404","article-title":"The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures","volume":"18","author":"Kaufman","year":"2007","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0595","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/cells7120274","article-title":"The role of mitochondria in reactive oxygen species generation and its implications for neurodegenerative diseases","volume":"7","author":"Kausar","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0600","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1083\/jcb.201709172","article-title":"Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases","volume":"216","author":"Kawamata","year":"2017","journal-title":"The Journal of Cell Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107705_bb0605","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4103\/1673-5374.211179","article-title":"Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway?","volume":"12","author":"Khalil","year":"2017","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0610","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/1570159X16666180828100002","article-title":"Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer\u2019s Disease: An Update","volume":"17","author":"Khan","year":"2019","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0615","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.expneurol.2004.10.007","article-title":"Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis","volume":"191","author":"Kiaei","year":"2005","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0620","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-6-53","article-title":"High-level inhibition of mitochondrial complexes III and IV is required to increase glutamate release from the nerve terminal","volume":"6","author":"Kilbride","year":"2011","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0625","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/bph.12413","article-title":"Turn up the power\u2013pharmacological activation of mitochondrial biogenesis in mouse models","volume":"171","author":"Komen","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0630","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/medicina55080485","article-title":"Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases","volume":"55","author":"Korta","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0635","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10571-017-0510-4","article-title":"BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity","volume":"38","author":"Kowia\u0144ski","year":"2018","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0640","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600963","article-title":"POLRMT regulates the switch between replication primer formation and gene expression of mammalian mtDNA","volume":"2","author":"K\u00fchl","year":"2016","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004385","article-title":"Loss of UCP2 attenuates mitochondrial dysfunction without altering ROS production and uncoupling activity","volume":"10","author":"Kukat","year":"2014","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0650","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbr.2008.10.010","article-title":"Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson\u2019s disease","volume":"197","author":"Kumar","year":"2009","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0655","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.phrs.2012.02.008","article-title":"Differential susceptibility to the PPAR\u03b3 agonist pioglitazone in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease","volume":"65","author":"Laloux","year":"2012","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0660","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.toxlet.2012.07.016","article-title":"Rosiglitazone, a PPAR\u03b3 agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats","volume":"213","author":"Lee","year":"2012","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0665","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.celrep.2016.12.090","article-title":"PINK1 primes Parkin-mediated ubiquitination of PARIS in dopaminergic neuronal survival","volume":"18","author":"Lee","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2020.107705_bb9238","doi-asserted-by":"crossref","first-page":"9695412","DOI":"10.1155\/2019\/9695412","article-title":"Mitochondria-and oxidative stress-targeting substances in cognitive decline-related disorders: from molecular mechanisms to clinical evidence","volume":"2019","author":"Lejri","year":"2019","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0670","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/antiox8050118","article-title":"Paraoxonases activities and polymorphisms in elderly and old-age diseases: an overview","volume":"8","author":"Levy","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0675","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/jnr.24042","article-title":"Mitochondrial biogenesis in neurodegeneration","volume":"95","author":"Li","year":"2017","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0680","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0685","doi-asserted-by":"crossref","first-page":"352723","DOI":"10.1155\/2015\/352723","article-title":"The ambiguous relationship of oxidative stress, tau hyperphosphorylation, and autophagy dysfunction in Alzheimer\u2019s disease","volume":"2015","author":"Liu","year":"2015","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0690","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41380-018-0266-3","article-title":"Novel upregulation of amyloid-beta precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5\u2019-untranslated region: Implications in Alzheimer\u2019s disease","volume":"24","author":"Long","year":"2019","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042878","article-title":"Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking PGC1\u03b1","volume":"7","author":"Lucas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0700","doi-asserted-by":"crossref","first-page":"3740461","DOI":"10.1155\/2018\/3740461","article-title":"Current concepts of neurodegenerative mechanisms in Alzheimer\u2019s disease","volume":"2018","author":"Magalingam","year":"2018","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0705","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/brain\/awp046","article-title":"Mitochondrial changes within axons in multiple sclerosis","volume":"132","author":"Mahad","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0710","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0715","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1523\/JNEUROSCI.5268-11.2012","article-title":"Mechanisms underlying the rapid peroxisome proliferator-activated receptor-\u03b3-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer\u2019s disease","volume":"32","author":"Mandrekar-Colucci","year":"2012","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0720","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1523\/JNEUROSCI.0848-17.2018","article-title":"Cell-specific deletion of PGC1\u03b1 from medium spiny neurons causes transcriptional alterations and age-related motor impairment","volume":"38","author":"McMeekin","year":"2018","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17352\/ojpdt.000001","article-title":"Restoration of mitochondrial dysfunction in 6-hydroxydopamine induced Parkinson's disease: A complete review","volume":"1","author":"Mehan","year":"2017","journal-title":"Open Journal of Parkinson's Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0730","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/jcbfm.2009.4","article-title":"Neuroprotective role of mitochondrial uncoupling protein 2 in cerebral stroke","volume":"29","author":"Mehta","year":"2009","journal-title":"Journal of Cerebral Blood Flow & Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0735","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fendo.2017.00140","article-title":"Importance of the sequence-directed DNA shape for specific binding site recognition by the estrogen-related receptor","volume":"8","author":"Mohideen-Abdul","year":"2017","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0740","first-page":"910502","article-title":"The Beta-amyloid protein of Alzheimer\u2019s disease: communication breakdown by modifying the neuronal cytoskeleton","volume":"2013","author":"Mokhtar","year":"2013","journal-title":"International Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0745","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"24","author":"Moon","year":"2015","journal-title":"Experimental Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0755","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.expneurol.2012.02.005","article-title":"Susceptibility to a parkinsonian toxin varies during primate development","volume":"235","author":"Morrow","year":"2012","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0760","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12944-016-0404-3","article-title":"Probing the intermolecular interactions of PPAR\u03b3-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties","volume":"16","author":"Muralikumar","year":"2017","journal-title":"Lipids in Health and Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0765","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainresbull.2011.03.011","article-title":"Protective effect of pioglitazone, a PPAR\u03b3 ligand, in a 3 nitropropionic acid model of Huntington's disease","volume":"85","author":"Napolitano","year":"2011","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0770","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1523\/JNEUROSCI.3413-13.2014","article-title":"Cognitive enhancing treatment with a PPAR\u03b3 agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice","volume":"34","author":"Nenov","year":"2014","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0775","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nsmb.2159","article-title":"Tfam, a mitochondrial transcription and packaging factor, imposes a U--turn on mitochondrial DNA","volume":"18","author":"Ngo","year":"2018","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0780","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","article-title":"Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor \u03b3 agonist","volume":"28","author":"Nicolakakis","year":"2008","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0785","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.biopsych.2017.12.014","article-title":"Peroxisome proliferator-activated receptor gamma coactivator-1 alpha as a novel target for bipolar disorder and other neuropsychiatric disorders","volume":"83","author":"Nierenberg","year":"2018","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0790","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00401-017-1708-8","article-title":"Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis","volume":"133","author":"Nijssen","year":"2017","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0795","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fnins.2019.00292","article-title":"The role of PGC1\u03b1\/UCP2 signaling in the beneficial effects of physical exercise on the brain","volume":"13","author":"de Oliveira Bristot","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0800","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12974-017-0957-8","article-title":"Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation","volume":"14","author":"Omeragic","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0805","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0810","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11910-018-0829-3","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease: new mechanistic insights and therapeutic perspectives","volume":"18","author":"Park","year":"2018","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106601","article-title":"DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress","volume":"9","author":"Parsanejad","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0820","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1111\/j.1582-4934.2009.00892.x","article-title":"Mitochondrial accumulation of APP and A\u03b2: significance for Alzheimer disease pathogenesis","volume":"13","author":"Pavlov","year":"2009","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0825","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1007\/s12035-016-9944-9","article-title":"The interaction of mitochondrial biogenesis and fission\/fusion mediated by PGC1\u03b1 regulates rotenone-induced dopaminergic neurotoxicity","volume":"54","author":"Peng","year":"2017","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0830","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fnins.2018.00441","article-title":"Contribution of tau pathology to mitochondrial impairment in neurodegeneration","volume":"12","author":"P\u00e9rez","year":"2018","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0835","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.freeradbiomed.2012.09.014","article-title":"Redox regulation of mitochondrial biogenesis","volume":"53","author":"Piantadosi","year":"2012","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0845","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1016\/j.cub.2018.01.004","article-title":"Mitophagy and quality control mechanisms in mitochondrial maintenance","volume":"28","author":"Pickles","year":"2018","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0850","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0855","doi-asserted-by":"crossref","first-page":"7348372","DOI":"10.1155\/2017\/7348372","article-title":"Uncoupling protein 2: A key player and a potential therapeutic target in vascular diseases","volume":"2017","author":"Pierelli","year":"2017","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0860","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","article-title":"Dynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson\u2019s disease","volume":"71","author":"Pisanu","year":"2014","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0865","doi-asserted-by":"crossref","first-page":"194586","DOI":"10.1155\/2011\/194586","article-title":"Strategies for reducing or preventing the generation of oxidative stress","volume":"2011","author":"Poljsak","year":"2011","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0870","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fnagi.2015.00204","article-title":"PGC1\u03b1 silencing compounds the perturbation of mitochondrial function caused by mutant SOD1 in skeletal muscle of ALS mouse model","volume":"7","author":"Qi","year":"2015","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0875","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archneurol.2008.588","article-title":"PGC1\u03b1 expression decreases in the Alzheimer disease brain as a function of dementia","volume":"66","author":"Qin","year":"2009","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0880","doi-asserted-by":"crossref","first-page":"25628","DOI":"10.1074\/jbc.M804291200","article-title":"Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells: possible role of peroxisome proliferator-activated receptor-\u03b3 (ppar\u03b3) in the pathogenesis of huntington disease","volume":"283","author":"Quintanilla","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0885","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/156720511795745401","article-title":"Mitochondria as a therapeutic target for aging and neurodegenerative diseases","volume":"8","author":"Reddy","year":"2011","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0890","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote","year":"2007","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0895","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.3390\/ijms12085285","article-title":"New aspects of mitochondrial uncoupling proteins (UCPs) and their roles in tumorigenesis","volume":"12","author":"Robbins","year":"2011","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0900","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbr.2010.08.002","article-title":"Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status","volume":"216","author":"Rodriguez-Rivera","year":"2011","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0905","doi-asserted-by":"crossref","first-page":"R1177","DOI":"10.1016\/j.cub.2017.09.015","article-title":"The origin and diversification of mitochondria","volume":"27","author":"Roger","year":"2017","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0910","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/1389450111314070002","article-title":"Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review","volume":"14","author":"Rolland","year":"2013","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0915","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.nbd.2012.08.015","article-title":"Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis","volume":"49","author":"Russell","year":"2013","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0920","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.76.052305.091720","article-title":"Mitochondrial-nuclear communications","volume":"76","author":"Ryan","year":"2007","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0925","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1074\/jbc.EC118.002682","article-title":"Exercise increases mitochondrial PGC-1 \u03b1 content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis","volume":"293","author":"Safdar","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0930","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/ijms19041091","article-title":"Emerging roles of estrogen-related receptors in the brain: potential interactions with estrogen signaling","volume":"19","author":"Saito","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0935","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bbamcr.2010.09.019","article-title":"Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network","volume":"1813","author":"Scarpulla","year":"2011","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0940","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1074\/jbc.M212923200","article-title":"The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor \u03b1 (ERR\u03b1)","volume":"278","author":"Schreiber","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0945","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1523\/JNEUROSCI.2038-05.2005","article-title":"The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice","volume":"25","author":"Sch\u00fctz","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0950","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.3390\/ijms19123893","article-title":"Mitochondrial dynamics in stem cells and differentiation","volume":"19","author":"Seo","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0955","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cells8020100","article-title":"Mitochondrial DNA integrity: role in health and disease","volume":"8","author":"Sharma","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0965","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1440-1789.2008.00890.x","article-title":"Effects of the PPAR\u03b3 activator pioglitazone on p38 MAP kinase and I\u03baB\u03b1 in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis","volume":"28","author":"Shibata","year":"2008","journal-title":"Neuropathology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0970","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC1\u03b1 contributes to neurodegeneration in Parkinson\u2019s disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0975","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1016\/j.cub.2014.12.006","article-title":"Mitochondrial biogenesis: cell-cycle-dependent investment in making mitochondria","volume":"25","author":"Shiota","year":"2015","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0980","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/ATVBAHA.108.181636","article-title":"Regulation of hypoxia-inducible genes by PGC1\u03b1","volume":"30","author":"Shoag","year":"2010","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0985","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2741\/4520","article-title":"Mitochondrial transcription in mammalian cells","volume":"22","author":"Shokolenko","year":"2017","journal-title":"Frontiers in Bioscience (Landmark edition)"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0990","doi-asserted-by":"crossref","first-page":"7361613","DOI":"10.1155\/2016\/7361613","article-title":"Overview of Alzheimer\u2019s disease and some therapeutic approaches targeting A\u03b2 by using several synthetic and herbal compounds","volume":"2016","author":"Singh","year":"2016","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb0995","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mito.2017.03.005","article-title":"Uncoupling protein 2 and metabolic diseases","volume":"34","author":"Sreedhar","year":"2017","journal-title":"Mitochondrion"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1000","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/biom5020356","article-title":"Impact of oxidative stress on exercising skeletal muscle","volume":"5","author":"Steinbacher","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1005","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1073\/pnas.1500624112","article-title":"Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration","volume":"112","author":"Stevens","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2007-11108","article-title":"Rosiglitazone induces mitochondrial biogenesis in mouse brain","volume":"11","author":"Strum","year":"2007","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1179\/1743132813Y.0000000305","article-title":"Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates","volume":"36","author":"Swanson","year":"2014","journal-title":"Neurological Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1020","doi-asserted-by":"crossref","first-page":"582809","DOI":"10.1155\/2013\/582809","article-title":"Neuroprotective properties of a novel non-thiazoledinedione partial PPAR\u03b3 agonist against MPTP","volume":"2013","author":"Swanson","year":"2013","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1030","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and mitochondrial cascades in Alzheimer\u2019s disease","volume":"62","author":"Swerdlow","year":"2018","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1326-6-32","article-title":"PGC-1alpha downstream transcription factors NRF1 and TFAM are genetic modifiers of Huntington disease","volume":"6","author":"Taherzadeh-Fard","year":"2011","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ceca.2012.03.003","article-title":"Regulation of ATP production by mitochondrial Ca2+","volume":"52","author":"Tarasov","year":"2012","journal-title":"Cell Calcium"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026961","article-title":"Fasting induces the expression of PGC1\u03b1 and ERR isoforms in the outer stripe of the outer medulla (OSOM) of the mouse kidney","volume":"6","author":"Teng","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2016.02.010","article-title":"UCP2 regulates mitochondrial fission and ventromedial nucleus control of glucose responsiveness","volume":"164","author":"Toda","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/mp.2009.72","article-title":"Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe\/PSEN1\u0394E9 mouse model of Alzheimer\u2019s disease","volume":"15","author":"Toledo","year":"2010","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1060","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/ars.2017.7342","article-title":"Transcriptional regulation by Nrf2","volume":"29","author":"Tonelli","year":"2018","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1065","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","article-title":"Oxidative stress, synaptic dysfunction, and Alzheimer\u2019s disease","volume":"57","author":"T\u00f6nnies","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JPD-160989","article-title":"PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson\u2019s disease pathobiology?","volume":"7","author":"Truban","year":"2017","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1075","doi-asserted-by":"crossref","first-page":"142ra97","DOI":"10.1126\/scitranslmed.3003799","article-title":"PGC1\u03b1 rescues Huntington\u2019s disease proteotoxicity by preventing oxidative stress and promoting TFEB function","volume":"4","author":"Tsunemi","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/molecules25051062","article-title":"Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?","volume":"25","author":"Tufano","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"Journal of Advanced Pharmaceutical Technology & Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1090","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.2174\/1381612820666140305224906","article-title":"Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases","volume":"20","author":"Uittenbogaard","year":"2014","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1095","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s12035-015-9124-3","article-title":"Resveratrol protects from toxin-induced parkinsonism: plethora of proofs hitherto petty translational value","volume":"53","author":"Ur Rasheed","year":"2016","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bbadis.2016.03.003","article-title":"The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model","volume":"1862","author":"Valenti","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbadis.2011.02.014","article-title":"PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation","volume":"1812","author":"Varga","year":"2011","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1110","doi-asserted-by":"crossref","first-page":"789764","DOI":"10.1155\/2013\/789764","article-title":"Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents","volume":"2013","author":"Viladomiu","year":"2013","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/febs.13175","article-title":"New insights into PGC-1 co-activators: redefining their role in the regulation of mitochondrial function and beyond","volume":"282","author":"Villena","year":"2015","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1120","doi-asserted-by":"crossref","first-page":"250126","DOI":"10.1155\/2010\/250126","article-title":"Coactivators in PPAR-regulated gene expression","volume":"2010","author":"Viswakarma","year":"2010","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1125","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.3390\/ijms18122772","article-title":"Nrf2, the master regulator of anti-oxidative responses","volume":"18","author":"Vomund","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1130","doi-asserted-by":"crossref","first-page":"14864","DOI":"10.1038\/s41598-017-14964-y","article-title":"Implications of mitochondrial network organization in mitochondrial stress signalling in NARP cybrid and Rho0 cells","volume":"7","author":"Walczak","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.gendis.2016.05.001","article-title":"Mitochondria as a therapeutic target in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2016","journal-title":"Genes & Diseases"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1140","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cmet.2013.03.016","article-title":"Metabolic stress modulates Alzheimer\u2019s \u03b2-secretase gene transcription via SIRT1-PPAR\u03b3-PGC-1 in neurons","volume":"17","author":"Wang","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2005.08.011","article-title":"Peroxisome proliferator-activated receptor \u03b3 in malignant diseases","volume":"58","author":"Wang","year":"2006","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1150","doi-asserted-by":"crossref","first-page":"27618","DOI":"10.1038\/srep27618","article-title":"Localization of PPAR isotypes in the adult mouse and human brain","volume":"6","author":"Warden","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1155","doi-asserted-by":"crossref","first-page":"810619","DOI":"10.4061\/2011\/810619","article-title":"Mitochondria and PGC1\u03b1 in aging and age-associated diseases","volume":"2011","author":"Wenz","year":"2011","journal-title":"Journal of Aging Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-14-1","article-title":"A single nucleotide polymorphism in the coding region of PGC-1alpha is a male-specific modifier of Huntington disease age-at-onset in a large European cohort","volume":"14","author":"Weydt","year":"2014","journal-title":"BMC Neurology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00401-012-1052-y","article-title":"Reduced expression of PGC1\u03b1 partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex","volume":"125","author":"Witte","year":"2013","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/BPL-150019","article-title":"FNDC5\/Irisin\u2013their role in the nervous system and as a mediator for beneficial effects of exercise on the brain","volume":"1","author":"Wrann","year":"2015","journal-title":"Brain Plasticity"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cmet.2013.09.008","article-title":"Exercise induces hippocampal BDNF through a PGC1\u03b1\/FNDC5 pathway","volume":"18","author":"Wrann","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mito.2019.07.003","article-title":"Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling","volume":"49","author":"Wu","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1185","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fendo.2018.00702","article-title":"Brain SIRT1 mediates metabolic homeostasis and neuroprotection","volume":"9","author":"Xu","year":"2018","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1190","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","article-title":"PPAR\u03b3\/RXR\u03b1-induced and CD36-mediated microglial amyloid-\u03b2 phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice","volume":"32","author":"Yamanaka","year":"2012","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1195","doi-asserted-by":"crossref","first-page":"403120","DOI":"10.1155\/2014\/403120","article-title":"Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases?","volume":"2014","author":"Yau","year":"2014","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnmol.2017.00164","article-title":"Mitochondrial Effects of PGC-1alpha Silencing in MPP+ Treated Human SH-SY5Y Neuroblastoma Cells","volume":"10","author":"Ye","year":"2017","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1205","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1126\/science.1219855","article-title":"Mitochondrial fission, fusion, and stress","volume":"337","author":"Youle","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1210","doi-asserted-by":"crossref","first-page":"6727421","DOI":"10.1155\/2018\/6727421","article-title":"Peroxisome proliferator-activated receptor \u03b3 and PGC1\u03b1 in cancer: dual actions as tumor promoter and suppressor","volume":"2018","author":"Yun","year":"2018","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1215","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1038\/s41598-017-07442-y","article-title":"Therapeutic effects of baicalein on rotenone-induced Parkinson\u2019s disease through protecting mitochondrial function and biogenesis","volume":"7","author":"Zhang","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1225","doi-asserted-by":"crossref","first-page":"52ra73","DOI":"10.1126\/scitranslmed.3001059","article-title":"PGC1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease","volume":"2","author":"Zheng","year":"2010","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fnmol.2018.00329","article-title":"A mitochondria-associated oxidative stress perspective on Huntington\u2019s Disease","volume":"11","author":"Zheng","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1235","first-page":"582","article-title":"Parkin functionally interacts with PGC1\u03b1 to preserve mitochondria and protect dopaminergic neuron s","volume":"26","author":"Zheng","year":"2017","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107705_bb1240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fnagi.2015.00101","article-title":"Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction","volume":"7","author":"Zorzano","year":"2015","journal-title":"Frontiers in Aging Neuroscience"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820302369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820302369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:12:50Z","timestamp":1759011170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820302369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":239,"alternative-id":["S0163725820302369"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107705","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR\u03b3\/PGC1\u03b1 signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107705"}}